Core Viewpoint - Galmed Pharmaceuticals Ltd. reported its financial results for the third quarter of 2025, highlighting a net loss and ongoing development of its lead product, Aramchol, for various medical indications, including liver disease and gastrointestinal oncology [1][6]. Financial Summary – Third Quarter 2025 vs. Third Quarter 2024 - Cash and cash equivalents totaled approximately $19.2 million as of September 30, 2025, an increase from $15.4 million at the end of 2024 [6]. - The net loss for the three months ended September 30, 2025, was approximately $2.0 million, or $0.33 per share, compared to a net loss of approximately $1.9 million, or $2.31 per share, for the same period in 2024 [6]. - Research and development expenses rose to approximately $1.1 million in Q3 2025 from $0.7 million in Q3 2024, primarily due to increased clinical and pre-clinical study costs [6]. - General and administrative expenses decreased to approximately $1.0 million in Q3 2025 from $1.3 million in Q3 2024, attributed to lower salaries and benefits [6]. Recent Business Updates - On November 17, 2025, Galmed announced positive results from a joint study with Virginia Commonwealth University, demonstrating that a combination of Aramchol, Stivarga®, and Metformin significantly enhanced the killing of gastrointestinal tumor cells both in vivo and in vitro [6][11]. - On November 18, 2025, the company reported meaningful results from its AM-001 Study, a Phase 1 bioavailability study of Aramchol Meglumine [6][11]. - In 2025, Galmed raised approximately $9.3 million through equity line and ATM facilities [6]. About Galmed Pharmaceuticals Ltd. - Galmed Pharmaceuticals is focused on developing Aramchol primarily for liver disease and is also exploring its potential in oncological indications beyond NASH and fibrosis [4]. - The company aims to expand and diversify its product pipeline, targeting cardiometabolic indications and other innovative drug candidates that align with its expertise in drug development [4].